Actively Recruiting
Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.
Led by IRCCS Centro Neurolesi Bonino Pulejo · Updated on 2025-12-17
151
Participants Needed
1
Research Sites
54 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the impact of dementia and MCI from a multidimensional perspective is now essential to fully grasp the repercussions of these conditions on patients' daily lives. The present protocol aims to investigate key aspects related to these disorders, with the objective of exploring cognitive functioning, the degree of impairment in activities of daily living, and the presence of neuropsychiatric symptoms. Through an integrated and multidisciplinary approach, the study seeks to enhance clinical management and patient care, promoting more effective, targeted, and personalized interventions.
CONDITIONS
Official Title
Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 50 and 86 years
- Suspected or confirmed diagnosis of dementia or mild cognitive impairment (MCI)
- Referral to the neuropsychology clinic for initial assessment or clinical monitoring
- Absence of behavioral, psychiatric, or sensory disorders severe enough to significantly impair cognitive testing or completion of questionnaires
You will not qualify if you...
- Presence of neurological disorders other than dementia or MCI, such as recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, or atypical neurodegenerative diseases
- Unstable major psychiatric comorbidities at the time of assessment, including schizophrenia, bipolar disorder in active phase, or untreated severe depression
- Severe uncorrected sensory deficits (visual or auditory) that affect the validity of cognitive or functional assessments
- Use of medications with significant cognitive impact, such as sedatives or high-dose antipsychotics, not stabilized at the time of evaluation
- Presence of terminal medical or oncological conditions or other illnesses that significantly interfere with assessment procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Irccs Centro Neurolesi Bonino Pulejo
Messina, ME, Italy, 98123
Actively Recruiting
Research Team
F
Francesco Corallo
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here